Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - enalapril maleate, quantity: 10 mg; lercanidipine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; povidone; lactose monohydrate; hypromellose; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; sodium bicarbonate; macrogol 6000 - treatment of hypertension. treatment should not be initiated with these fixed dose combinations. (see dosage and administration).

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets are indicated for the treatment of hypertension. enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. heart failure enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets improve symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decreases the incidence of hospitalization for hea

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets are indicated for the treatment of hypertension. enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. heart failure enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets improve symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decreases the incidence of hospitalization for hea

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets are indicated for the treatment of hypertension. enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. heart failure enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets improve symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decreases the incidence of hospitalization for hea

United States - English - NLM (National Library of Medicine)

directrx - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. heart failure enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacolo

United States - English - NLM (National Library of Medicine)

bausch health us llc - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 2.5 mg - hypertension vasotec is indicated for the treatment of hypertension. vasotec is effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of vasotec and thiazides are approximately additive. heart failure vasotec is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients vasotec improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), vasotec decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of surv

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - enalapril maleate, quantity: 20 mg - tablet, uncoated - excipient ingredients: maize starch; sodium bicarbonate; lactose monohydrate; magnesium stearate; pregelatinised maize starch; colour - hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril maleate be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; iron oxide red; sodium bicarbonate; pregelatinised maize starch; magnesium stearate - hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril maleate be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - enalapril maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: maize starch; sodium bicarbonate; lactose monohydrate; hyprolose; purified talc; magnesium stearate - indications: hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that noumed enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - enalapril maleate, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; hypromellose; maleic acid; croscarmellose sodium; sodium stearylfumarate - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.